Canaccord Genuity Group Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $62.00 price objective on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price target points to a potential upside of 139.20% from the stock’s current […]
More Stories
The Best Food Scene You Don’t Know About Is in Buffalo, New York
By Adam Reiner, Bloomberg News Buffalo might be synonymous with hot wings, but there’s a less heralded bar staple that...
The Best Food Scene You Don’t Know About Is in Buffalo, New York
By Adam Reiner, Bloomberg News Buffalo might be synonymous with hot wings, but there’s a less heralded bar staple that...
Your Brain’s Secret Defense Against Alzheimer’s
By Brendon Fallon and Lynn Xu For many people, Alzheimer’s disease casts an increasingly large shadow as mental fog, forgotten...
Your Brain’s Secret Defense Against Alzheimer’s
By Brendon Fallon and Lynn Xu For many people, Alzheimer’s disease casts an increasingly large shadow as mental fog, forgotten...
Rivian Recalls Nearly 35,000 Delivery Vans Over Seat Belt Misuse Issue
By Rob Sabo Electric vehicle (EV) manufacturer Rivian Automotive announced on Dec. 3 it is recalling 34,824 delivery vans due...
Rivian Recalls Nearly 35,000 Delivery Vans Over Seat Belt Misuse Issue
By Rob Sabo Electric vehicle (EV) manufacturer Rivian Automotive announced on Dec. 3 it is recalling 34,824 delivery vans due...